Quality Assurance Evolution in the Biopharmaceutical CDMO Industry – stricter regulations, technological advancements, risk management, globalisation and client expectations.

Generally Speaking, How Has Quality Assurance in Drug Manufacturing Evolved Over the Past 10 years?
In the last ten years, quality assurance in biologics drug manufacturing has greatly improved due to several important factors:
• Regulatory Evolution: Global regulatory standards have become stricter, with agencies like the FDA and EMA updating their guidelines to ensure drugs are safe and effective. This has pushed drug manufacturers worldwide to upgrade their quality systems to comply with current Good Manufacturing Practices (cGMP) and other regulatory requirements.
• Technology Advancements: New technologies, including automation and data analytics, have enhanced the precision and efficiency of quality assurance. Innovations such as single-use systems in manufacturing have also significantly lowered contamination risks and improved product consistency.
• Risk Management: There’s an increased focus on risk-based quality management. Principles of Quality by Design (QbD) and risk management are now essential in both development and manufacturing, aiming to better understand and control process variables.
• Globalisation: As CDMOs go global and serve clients worldwide, they need to standardise quality assurance across different countries and regulatory frameworks. This has led to more unified global quality standards.
• Client Expectations: With biologics becoming more complex, clients are seeking higher quality and greater transparency in manufacturing. CDMOs have responded by enhancing their quality assurance systems and improving communication with clients about quality metrics.

Overall, the quality assurance in biologics manufacturing within CDMOs has become more sophisticated, compliant with regulations, and aligned with technological and market changes to meet the high standards required for biologics products.